A new drug has been found to slow the progression of Alzheimer's, with experts hailing it as a "turning point" in the fight against the disease.
Following the findings of a trial of the drug, Alzheimer's Research UK said "we're entering a new era" where the disease "could become treatable".
The health spending watchdog in England, the National Institute for Health and Care Excellence (NICE), is already assessing whether the drug can be used in the NHS.
Alzheimer's Society said treatments such as donanemab could one day mean the disease is comparable to long-term conditions such as asthma or diabetes.
Donanemab works by removing plaques of a protein called amyloid that build up in the brain of people with Alzheimer's.
Scientists have published the final results of a trial, known as TRAILBLAZER ALZ-2, examining the safety and efficacy of the drug, manufactured by US pharmaceutical giant Eli Lilly.
The researchers found among a small number of people there were some serious side effects such as brain swelling. »